Key result
A multi-SNP genotypic risk score of adiponectin-decreasing alleles was associated with increased risk of type 2 diabetes (p=4.3×10^-3) and altered metabolic traits.
Why the study?
Do genetic determinants of adiponectin levels influence the risk of type 2 diabetes and metabolic traits?
Meta-Analysis (n=45,891)
Yes
Do genetic determinants of adiponectin levels influence the risk of type 2 diabetes and metabolic traits?
p-value: p=4.5×10(-8)-1.2×10(-43)
Novel genetic determinants of adiponectin levels are significantly associated with the risk of type 2 diabetes and markers of insulin resistance.
Supports adiponectin genetics in type 2 diabetes etiology; leaves open whether levels are modifiable therapeutic targets.
Circulating levels of adiponectin, a hormone produced predominantly by adipocytes, are highly heritable and are inversely associated with type 2 diabetes mellitus (T2D) and other metabolic traits. We conducted a meta-analysis of genome-wide association studies in 39,883 individuals of European ancestry to identify genes associated with metabolic disease. We identified 8 novel loci associated with adiponectin levels and confirmed 2 previously reported loci (P = 4.5×10(-8)-1.2×10(-43)). Using a novel method to combine data across ethnicities (N = 4,232 African Americans, N = 1,776 Asians, and N = 29,347 Europeans), we identified two additional novel loci. Expression analyses of 436 human adipocyte samples revealed that mRNA levels of 18 genes at candidate regions were associated with adiponectin concentrations after accounting for multiple testing (p<3×10(-4)). We next developed a multi-SNP genotypic risk score to test the association of adiponectin decreasing risk alleles on metabolic traits and diseases using consortia-level meta-analytic data. This risk score was associated with increased risk of T2D (p = 4.3×10(-3), n = 22,044), increased triglycerides (p = 2.6×10(-14), n = 93,440), increased waist-to-hip ratio (p = 1.8×10(-5), n = 77,167), increased glucose two hours post oral glucose tolerance testing (p = 4.4×10(-3), n = 15,234), increased fasting insulin (p = 0.015, n = 48,238), but with lower in HDL-cholesterol concentrations (p = 4.5×10(-13), n = 96,748) and decreased BMI (p = 1.4×10(-4), n = 121,335). These findings identify novel genetic determinants of adiponectin levels, which, taken together, influence risk of T2D and markers of insulin resistance.
No takes yet. Share an insight, caveat, or question.
Dastani et al. (2012) conducted a meta-analysis in Type 2 Diabetes and Metabolic Traits (n=45,891). Adiponectin decreasing risk alleles was evaluated on Adiponectin levels (p=4.5×10(-8)-1.2×10(-43)). A multi-SNP genotypic risk score of adiponectin-decreasing alleles was associated with increased risk of type 2 diabetes (p=4.3×10^-3) and altered metabolic traits.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: